METOCLOPRAMIDE HYDROCHLORIDE INJECTION SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

METOCLOPRAMIDE DIHYDROCHLORIDE (METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE)

Beszerezhető a:

JAMP PHARMA CORPORATION

ATC-kód:

A03FA01

INN (nemzetközi neve):

METOCLOPRAMIDE

Adagolás:

5MG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

METOCLOPRAMIDE DIHYDROCHLORIDE (METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE) 5MG

Az alkalmazás módja:

INTRAMUSCULAR

db csomag:

15G/50G

Recept típusa:

Prescription

Termék összefoglaló:

Active ingredient group (AIG) number: 0164581001; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2023-04-21

Termékjellemzők

Metoclopramide Hydrochloride Injection - Product Monograph
Page 1 of 18
PRODUCT MONOGRAPH
PR
METOCLOPRAMIDE HYDROCHLORIDE INJECTION
5 mg / mL
Metoclopramide Hydrochloride (as metoclopramide
hydrochloride monohydrate)
House Standard
Sterile
MODIFIER OF UPPER GASTROINTESTINAL TRACT MOTILITY– ANTIEMETIC
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Preparation:
April 20, 2023
Control No: 265455
Metoclopramide Hydrochloride Injection - Product Monograph
Page 2 of 18
PR
METOCLOPRAMIDE HYDROCHLORIDE INJECTION
5 MG / ML
HOUSE STANDARD
THERAPEUTIC CLASSIFICATION
Modifier of Upper Gastrointestinal Tract Motility– Antiemetic
ACTION AND CLINICAL PHARMACOLOGY
Metoclopramide is a benzamide derivative structurally related to
procainamide and sulpiride. It
has a dopamine antagonist activity with selective affinity for D2
(nonadenylate cyclase linked)
receptors. The behavioural, motor and neuroendocrine effects of
metoclopramide have been
suggested to be due to its antidopaminergic activity.
Metoclopramide has antiemetic properties which are believed to result
from its action on the
chemoreceptor trigger zone. A peripheral mechanism of action may also
be involved.
Metoclopramide raises resting pressure in the lower esophageal
sphincter and the gastric
fundus and gives rise to an increase in the amplitude of peristaltic
movements in the
esophagus, gastric antrum and small intestine. As a consequence,
esophageal clearance is
hastened, gastric emptying accelerated and transit time through the
small bowel shortened.
These effects are blocked by atropine and opioids but not by vagotomy.
Metoclopramide elevates serum prolactin and causes transient increases
in circulating
aldosterone levels. These effects are thought to be due to blockade of
dopamine receptors at
the pituitary and adrenocortical cellular level.
Following intravenous administration, peak plasma levels occur within
minutes. The terminal
half-life is approximately 3 hours but this is prolonged in patients
with impaired renal
func